Skip to main content

InflaRx Stock Forecast, Price & News

+0.07 (+2.57 %)
(As of 05/14/2021 02:58 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume9,442 shs
Average Volume385,941 shs
Market Capitalization$120.61 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

InflaRx logo

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IFRX
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$4.62 per share


Net Income$-59,650,000.00




Market Cap$120.61 million
Next Earnings Date7/29/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.37 out of 5 stars

Medical Sector

740th out of 2,039 stocks

Pharmaceutical Preparations Industry

347th out of 769 stocks

Analyst Opinion: 3.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

InflaRx (NASDAQ:IFRX) Frequently Asked Questions

Is InflaRx a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" InflaRx stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IFRX, but not buy additional shares or sell existing shares.
View analyst ratings for InflaRx
or view top-rated stocks.

What stocks does MarketBeat like better than InflaRx?

Wall Street analysts have given InflaRx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InflaRx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is InflaRx's next earnings date?

InflaRx is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for InflaRx

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) released its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05.
View InflaRx's earnings history

How has InflaRx's stock been impacted by COVID-19 (Coronavirus)?

InflaRx's stock was trading at $3.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IFRX stock has decreased by 13.6% and is now trading at $2.79.
View which stocks have been most impacted by COVID-19

What price target have analysts set for IFRX?

9 brokerages have issued 12-month price objectives for InflaRx's shares. Their forecasts range from $2.80 to $16.00. On average, they expect InflaRx's stock price to reach $9.48 in the next twelve months. This suggests a possible upside of 239.6% from the stock's current price.
View analysts' price targets for InflaRx
or view top-rated stocks among Wall Street analysts.

Who are InflaRx's key executives?

InflaRx's management team includes the following people:
  • Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 49)
  • Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 51)
  • Dr. Thomas Taapken Ph.D., Chief Financial Officer (Age 56)
  • Mr. Jordan Silverstein, Head of Corp. Devel. & Strategy
  • Dr. Maria Habel PH.D., Head of Preclinical R&D (Age 39)
  • Ms. Katrin Reiher, Head of Quality Management (Age 39)
  • Mr. Jordan Zwick, Chief Strategy Officer (Age 34)
  • Dr. Korinna Pilz, Global Head of Clinical R&D

Who are some of InflaRx's key competitors?

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), (KDMN) and Moderna (MRNA).

When did InflaRx IPO?

(IFRX) raised $100 million in an IPO on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is InflaRx's stock symbol?

InflaRx trades on the NASDAQ under the ticker symbol "IFRX."

Who are InflaRx's major shareholders?

InflaRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Altium Capital Management LP (1.79%), Granite Point Capital Management L.P. (0.88%), Eversept Partners LP (0.62%), QS Investors LLC (0.40%), Renaissance Technologies LLC (0.29%) and Franklin Street Advisors Inc. NC (0.17%).

Which major investors are selling InflaRx stock?

IFRX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Occudo Quantitative Strategies LP, and Personal CFO Solutions LLC.

Which major investors are buying InflaRx stock?

IFRX stock was bought by a variety of institutional investors in the last quarter, including Altium Capital Management LP, Granite Point Capital Management L.P., Eversept Partners LP, QS Investors LLC, Axiom Investment Management LLC, Franklin Street Advisors Inc. NC, Algert Global LLC, and Pacifica Partners Inc..

How do I buy shares of InflaRx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InflaRx's stock price today?

One share of IFRX stock can currently be purchased for approximately $2.79.

How much money does InflaRx make?

InflaRx has a market capitalization of $120.61 million. The company earns $-59,650,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does InflaRx have?

InflaRx employs 47 workers across the globe.

What is InflaRx's official website?

The official website for InflaRx is

Where are InflaRx's headquarters?

InflaRx is headquartered at WINZERLAER STR. 2, JENA 2M, 07745.

How can I contact InflaRx?

InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180 or via email at [email protected]

This page was last updated on 5/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.